Drug-associated dermatomyositis following ipilimumab therapy: A novel immune-mediated adverse event associated with cytotoxic t-lymphocyte antigen 4 blockade

JAMA Dermatology

Volumn 151, Issue 2, 2015, Pages 195-199

  Ali, Shirwa Sheik ^a   Goddard, Allison L ^b,c   Luke, Jason J ^c   Donahue, Hilary ^c   Todd, Derrick J ^d   Werchniak, Andrew ^b,c   Vleugels, Ruth Ann ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CREATINE KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; FRUCTOSE BISPHOSPHATE ALDOLASE; IPILIMUMAB; METHYLPREDNISOLONE; MUSCLE ENZYME; PREDNISONE; TRAMETINIB; MONOCLONAL ANTIBODY;

ADULT; ADVERSE OUTCOME; ANTIBODY TITER; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG RECHALLENGE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOMODULATION; LABORATORY TEST; METASTATIC MELANOMA; MIDDLE AGED; MUSCLE BIOPSY; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCULOSKELETAL SYSTEM EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RETREATMENT; SKIN EXAMINATION; SKIN MANIFESTATION; SPINE RADIOGRAPHY; TUMOR LOCALIZATION; CELLULAR IMMUNITY; CHEMICALLY INDUCED; DRUG EFFECTS; IMMUNOLOGY; MELANOMA; PATHOLOGY; SKIN; SKIN NEOPLASMS; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNITY, CELLULAR; MELANOMA; MIDDLE AGED; SKIN; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 84922945447     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.2233     Document Type: Article

References (15)

1. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527-534.
2. Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo). 2013;2013.
3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8): 711-723.
4. Ibrahim RA, Berman DM, DePril V, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma [abstract 8583]. J Clin Oncol. 2011;29(15 suppl).
5. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30 (21):2691-2697.
6. Dummer R, Maoi M, Hamid O, et al. Time to onset and resolution of immune-related adverse events associated with ipilimumab therapy in patients with advanced melanoma. In: Proceedings of the 14th Perspectives in Melanoma; September 16, 2010; Amsterdam, the Netherlands.
7. Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4. Arthritis Rheumatol. 2014;66(3):768-769.
8. Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009;361(2):211-212.
9. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283-2289.
10. Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S; MDX010-20 investigators. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res. 2013;19(8):2232-2239.
11. Barnes BE, Mawr B. Dermatomyositis and malignancy. Ann Intern Med. 1976;84(1):68-76.
12. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343 (6167):152-157.
13. Seidler AM, Gottlieb AB. Dermatomyositis induced by drug therapy: a review of case reports. J Am Acad Dermatol. 2008;59(5):872-880.
14. Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146(7):780-784.
15. Liu SW, Velez NF, Lam C, et al. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. JAMA Dermatol. 2013;149(10):1204-1208.